Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Production / Operations Routine +

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage(TM) in China

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

By The Northwire Desk — AI Analysis May 28, 2026 · 16:15 BHC · 7.48 BAUSCH HEALTH COMPANIES INC.
Executive Summary
  • Bausch Health's aesthetic business, Solta Medical, received AAA Well-Known Trademark Certification for Thermage® in China from the China Trademark Association.
  • This certification is reserved for top-tier brands with exceptional market influence; only 217 brands across mainland China have achieved this status.
  • The distinction validates Thermage's reliability and consumer confidence following over a decade of presence and 5 million treatments worldwide.
  • Management views the rating as a "mark of trust" allowing consumers to choose Thermage® with confidence in legitimacy and product integrity.
  • This follows the Q1 2026 earnings release where Solta Medical reported $171 million revenue, up 51% reported (19% organic), driven by the Shibo acquisition integration in China.
Material Impact
  • The news is positive but largely incremental to existing market expectations established during Q1 2026 earnings and the December 2025 Shibo acquisition announcement.
  • Solta's strong performance in China (193% organic growth surge reported in transcript) has already been priced into the stock; this certification serves as brand validation rather than a new revenue catalyst.
  • No immediate financial impact is quantified, but it strengthens the moat for Thermage® in a key growth geography against competitors.
  • The market reaction will likely be muted compared to clinical trial results or major M&A announcements given the routine nature of trademark renewals/certifications for established brands.
BHC · Price
Company Overview
  • Company: Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company with portfolios in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health.
  • Flagship Projects:
    • Solta Medical: Aesthetics division featuring Thermage® (skin tightening) and Clear + Brilliant Touch laser systems; key growth driver in APAC/China.
    • Salix Segment: Gastroenterology focus with Xifaxan® (hepatic encephalopathy, IBS-D), the primary revenue generator for Bausch Health excluding B+L.
    • Bausch + Lomb: Eye health segment contributing $1.24 billion in Q1 2026 revenue.
  • Development Status: Larsucosterol Phase 3 ongoing for alcohol-associated hepatitis; RED-C program failed primary endpoint in Jan 2026.
Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jul 01, 2026 · 16:15

Michael Goettler Resigns from Bausch Health's Board of Directors

Management Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 19, 2026 · 16:15

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

Regulatory May 12, 2026 · 16:15

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Other Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other